CD40 Ligand Blockade for Prevention of Graft-Versus-Host Disease This scoping review was conducted based on the Arksey and O'Malley framework and the work of Levac et al. The databases searched ...

There were approximately 725,000 new cases and 664,000 deaths worldwide due to hepatocellular carcinoma (HCC) in 2020. HCC comprises 75%-85% of primary liver cancer cases and is the fourth-leading ...

Patients 65 years and older with previously untreated MCL received acalabrutinib (100 mg twice daily) or placebo (until disease progression or unacceptable toxicity), plus six cycles of bendamustine ...

Most patients with pancreatic adenocarcinoma present with advanced disease at diagnosis, 1 which remains difficult to treat. With 5-year survival rates between 8% and 13%, 1,2 prognosis for patients ...

Depending upon prior treatment received, androgen receptor pathway inhibitors (ARPIs: enzalutamide, abiraterone with prednisone), poly(ADP-ribose) polymerase inhibitors (PARPi), chemotherapeutic ...

PCS involves extensive surgical effort to achieve optimal debulking, defined as no residual tumor or minimal residual disease. This approach has been associated with improved survival rates when ...

Fig 1.Management of the axilla for patients with clinical T ≤2 cm breast cancer. a Multidisciplinary discussion of adjuvant therapy options should occur prior to surgery when omitting sentinel lymph ...

The purpose of this clinical practice guideline is to provide referring and imaging clinicians (including medical oncologists, radiation oncologists, urologists, radiologists, nuclear medicine ...

ASCO–Society for Integrative Oncology (SIO) Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline ...

The cyclin-dependent kinase 4/6 (CDK4/6) inhibitors palbociclib, abemaciclib, and ribociclib each showed a significant or strong trend to improve overall survival (OS) when given as second-line ...

Axillary staging for breast cancer has been a standard part of initial surgical treatment since 2002 when Fisher et al published the National Surgical Adjuvant Breast and Bowel Project (NSABP) B06, 1 ...

Over the past two decades, monoclonal antibodies (mAbs) have played a pivotal role in cancer treatment; however, their efficacy as anticancer agents is constrained by tumor heterogeneity and the ...